Reversible cerebral vasoconstriction syndrome associated with interferon beta-1a use for multiple sclerosis

Area of Science:

• Neurology
• Pharmacology

Background:

• Reversible cerebral vasoconstriction syndrome (RCVS) is a condition characterized by temporary narrowing of brain arteries.
• RCVS has been linked to various triggers including medications, illicit drugs, pregnancy, and migraines.

Observation:

• A 20-year-old female with multiple sclerosis (MS) developed sudden, severe headaches.
• The patient had started Rebif (Interferon beta-1a) two months prior to symptom onset.

Findings:

• Cerebral angiography revealed multifocal distal arterial stenosis and dilatations, consistent with RCVS.
• Radiographic evidence of RCVS resolved within one month of observation.

Implications:

• This case represents the first documented instance of RCVS associated with interferon beta-1a (Rebif) treatment in an MS patient.
• Clinicians should consider RCVS as a potential complication in multiple sclerosis patients treated with interferon beta therapies.
• Further investigation into the relationship between interferon beta and RCVS is warranted.